Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

Safety and Efficacy of U3-1402 in Advanced or Metastatic Colorectal Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if the study drug, U3-1402, is safe and effective for shrinking your tumors.

What is the Condition Being Studied?

Colorectal Adenocarcinoma

Who Can Participate in the Study?

Adults with colorectal adenocarcinma who:
-Have advanced or metastatic disease
-Failed at least 2 prior lines of therapy

Age Group

What is Involved?

If you choose to join this study, you will:
-Get the study drug, U3-1402, by I.V. once every 3 weeks
-Give blood and urine samples
-Have regular CT or MRI scans

Study Details

Full Title
[U31402-A-U202] A Multi-Center, Open-Label, Phase 2 Study to Evaluate Safety and Efficacy of U3-1402 in Subjects with Advanced or Metastatic Colorectal Cancer (CRC)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00105856
NCT: NCT04479436
Phase II
Enrollment Status
Open for Enrollment Soon
More Information
Contact the Duke Recruitment Innovation Center